ERBB2 and breast cancer: Trastuzumab, initially for HER2+ breast cancer, targets HER2 tyrosine kinase activity critical for cell proliferation, which is present also in osteosarcoma cells, indicating its potential for osteosarcoma therapy (84, 85).